secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001607062-24-000053
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma files provisional patent for stem cell endothelial therapy to speed hematopoietic recovery
--------------------------------------------------------------------------------

- Filed a provisional patent application with the USPTO on February 7, 2024.
- Covers compositions, protocols, and treatment means for accelerating hematopoietic reconstitution.
- Targets recovery after insult or chronic pathology using stem cell-derived endothelial progenitor or endothelial cells.
- Application protects a potential regenerative medicine therapy for bone marrow or blood cell restoration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706224000053/0001607062-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706224000053/rgbp020924form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer